Analysts expect that Corium International Inc (NASDAQ:CORI) will report $7.07 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Corium International’s earnings, with the highest sales estimate coming in at $7.57 million and the lowest estimate coming in at $6.57 million. Corium International posted sales of $7.35 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 3.8%. The company is scheduled to report its next earnings report on Thursday, May 10th.
On average, analysts expect that Corium International will report full-year sales of $7.07 million for the current financial year, with estimates ranging from $31.97 million to $33.93 million. For the next fiscal year, analysts forecast that the firm will report sales of $39.28 million per share, with estimates ranging from $38.82 million to $39.74 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Corium International.
Corium International (NASDAQ:CORI) last issued its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. Corium International had a negative net margin of 148.07% and a negative return on equity of 403.15%. The business had revenue of $9.32 million for the quarter, compared to analysts’ expectations of $7.48 million.
A number of brokerages recently weighed in on CORI. BidaskClub cut shares of Corium International from a “buy” rating to a “hold” rating in a research note on Tuesday. HC Wainwright set a $14.00 price objective on shares of Corium International and gave the company a “buy” rating in a research note on Friday, February 9th. ValuEngine raised Corium International from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Zacks Investment Research lowered Corium International from a “hold” rating to a “sell” rating in a report on Friday, December 29th. Finally, Needham & Company LLC lifted their target price on Corium International from $13.00 to $16.00 and gave the stock a “buy” rating in a report on Monday, November 20th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $12.86.
Shares of Corium International (NASDAQ:CORI) opened at $11.92 on Thursday. Corium International has a one year low of $3.50 and a one year high of $13.93. The company has a debt-to-equity ratio of 5.91, a quick ratio of 1.34 and a current ratio of 1.40.
In other news, major shareholder Life Sciences Maste Perceptive bought 510,000 shares of the stock in a transaction that occurred on Thursday, January 18th. The shares were purchased at an average cost of $12.54 per share, with a total value of $6,395,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Perceptive Advisors Llc bought 50,350 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were purchased at an average cost of $11.83 per share, for a total transaction of $595,640.50. The disclosure for this purchase can be found here. 30.80% of the stock is owned by insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Candriam Luxembourg S.C.A. increased its stake in Corium International by 377.8% in the 4th quarter. Candriam Luxembourg S.C.A. now owns 86,000 shares of the biopharmaceutical company’s stock worth $826,000 after purchasing an additional 68,000 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Corium International by 33.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 88,445 shares of the biopharmaceutical company’s stock worth $980,000 after purchasing an additional 22,285 shares in the last quarter. Tamarack Advisers LP increased its stake in Corium International by 6.3% in the 4th quarter. Tamarack Advisers LP now owns 1,010,000 shares of the biopharmaceutical company’s stock worth $9,706,000 after purchasing an additional 60,000 shares in the last quarter. TIAA CREF Investment Management LLC purchased a new position in Corium International in the 2nd quarter worth about $411,000. Finally, Emory University purchased a new position in Corium International in the 4th quarter worth about $1,615,000. 88.58% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/03/15/7-07-million-in-sales-expected-for-corium-international-inc-cori-this-quarter-2.html.
About Corium International
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Get a free copy of the Zacks research report on Corium International (CORI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.